- Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma - Paris , 04 July.
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions .
Ipsen s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients .
This follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021 Paris , Friday 13 August, 2021 - Ipsen today.
PARIS, France, 27 October 2021 - Ipsen today has pledged to play its part in securing global net-zero emissions, ahead of the COP26 conference in Glasgow, UK, next month. Ipsen is proud to.